{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:34:40Z","timestamp":1784752480991,"version":"3.55.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1053\/j.seminoncol.2017.02.001","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T10:45:25Z","timestamp":1486809925000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Screening for prostate cancer"],"prefix":"10.1053","volume":"44","author":[{"given":"Rosalyn W.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lizama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Peairs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather F.","family":"Sateia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngjee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2017.02.001_bib1","series-title":"Cancer manual","first-page":"284","article-title":"Cancer of the prostate","author":"Shipley","year":"1990"},{"issue":"22","key":"10.1053\/j.seminoncol.2017.02.001_bib2","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1001\/archinte.1993.00410220025003","article-title":"An evaluation of prostate-specific antigen as a screening test for prostate cancer","volume":"153","author":"Dorr","year":"1993","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.02.001_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.02.001_bib5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/1078-0432.CCR-08-1822","article-title":"Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations","volume":"15","author":"Agalliu","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.02.001_bib6","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1053\/j.seminoncol.2017.02.001_bib7","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1158\/1078-0432.CCR-03-0604","article-title":"BRCA mutations and risk of prostate cancer in Ashkenazi Jews","volume":"10","author":"Kirchhoff","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib8","unstructured":"SEER Stat Fact Sheets: Prostate Cancer 2015. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed April 28, 2015."},{"issue":"19","key":"10.1053\/j.seminoncol.2017.02.001_bib9","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/jnci\/djp278","article-title":"Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986\u20132005","volume":"101","author":"Welch","year":"2009","journal-title":"J Nat Cancer Inst"},{"issue":"8892","key":"10.1053\/j.seminoncol.2017.02.001_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0140-6736(94)91109-6","article-title":"Changes in prostate cancer incidence and treatment in USA","volume":"343","author":"Lu-Yao","year":"1994","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib11","series-title":"SEER cancer statistics review, 1975\u20132008","year":"2011"},{"issue":"5","key":"10.1053\/j.seminoncol.2017.02.001_bib12","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.juro.2010.01.015","article-title":"Evidence supports a faster growth rate and\/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity","volume":"183","author":"Powell","year":"2010","journal-title":"J Urol"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.02.001_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju489","article-title":"Age at cancer diagnosis for blacks compared with whites in the United States","volume":"107","author":"Robbins","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.02.001_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cdp.2006.11.004","article-title":"Earlier age at diagnosis: another dimension in cancer disparity?","volume":"31","author":"Karami","year":"2007","journal-title":"Cancer Detect Prev"},{"issue":"14","key":"10.1053\/j.seminoncol.2017.02.001_bib15","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/pros.20825","article-title":"Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era","volume":"68","author":"Chen","year":"2008","journal-title":"Prostate"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.juro.2014.09.018","article-title":"Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator","volume":"193","author":"Grill","year":"2015","journal-title":"J Urol"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.02.001_bib17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/bju.13310","article-title":"A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau)","volume":"117","author":"Randazzo","year":"2016","journal-title":"BJU Int"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.02.001_bib18","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0022-5347(05)64541-7","article-title":"Hereditary prostate cancer: clinical aspects","volume":"168","author":"Bratt","year":"2002","journal-title":"J Urol"},{"issue":"8","key":"10.1053\/j.seminoncol.2017.02.001_bib19","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1073\/pnas.89.8.3367","article-title":"Mendelian inheritance of familial prostate cancer","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"35","key":"10.1053\/j.seminoncol.2017.02.001_bib20","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1200\/JCO.2012.43.2278","article-title":"Risks of less common cancers in proven mutation carriers with lynch syndrome","volume":"30","author":"Engel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.02.001_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/gim.2013.193","article-title":"Prostate cancer incidence in males with Lynch syndrome","volume":"16","author":"Haraldsdottir","year":"2014","journal-title":"Genet Med"},{"issue":"14","key":"10.1053\/j.seminoncol.2017.02.001_bib22","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1055-9965.EPI-13-1165","article-title":"Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis","volume":"23","author":"Ryan","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/jnci\/djs351","article-title":"Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome","volume":"104","author":"Win","year":"2012","journal-title":"J Nat Cancer Inst"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib25","unstructured":"National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review, 1975-2004 2007. Available at: http:\/\/seer.cancer.gov\/csr\/1975_2004\/. Accessed April 26, 2012."},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","article-title":"Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations","volume":"11","author":"Moran","year":"2012","journal-title":"Fam Cancer"},{"issue":"9","key":"10.1053\/j.seminoncol.2017.02.001_bib28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jmg.2004.028829","article-title":"Cancer risks in BRCA2 families: estimates for sites other than breast and ovary","volume":"42","author":"Van Asperen","year":"2005","journal-title":"J Med Genet"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib29","first-page":"154","article-title":"Survival rates of familial and sporadic prostate cancer patients","volume":"37","author":"Plonis","year":"2015","journal-title":"Exp Oncol"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib30","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1038\/srep10544","article-title":"A family history of lethal prostate cancer and risk of aggressive prostate cancer in patients undergoing radical prostatectomy","volume":"5","author":"Raheem","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.02.001_bib31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1186\/s12885-016-2891-z","article-title":"Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta\u2013analysis","volume":"16","author":"Zhao","year":"2016","journal-title":"BMC Cancer"},{"issue":"15","key":"10.1053\/j.seminoncol.2017.02.001_bib32","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"8899","key":"10.1053\/j.seminoncol.2017.02.001_bib33","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"issue":"10","key":"10.1053\/j.seminoncol.2017.02.001_bib34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","article-title":"Germline BRCA1 mutations increase prostate cancer risk","volume":"106","author":"Leongamornlert","year":"2012","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.02.001_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","article-title":"Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature","volume":"22","author":"Liede","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.02.001_bib36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jmg.39.7.457","article-title":"The effect of a single BRCA2 mutation on cancer in Iceland","volume":"39","author":"Tulinius","year":"2002","journal-title":"J Med Genet"},{"issue":"14","key":"10.1053\/j.seminoncol.2017.02.001_bib37","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/sj.bjc.6604132","article-title":"Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype","volume":"98","author":"Mitra","year":"2008","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.bjc.6604453","article-title":"Rapid progression of prostate cancer in men with a BRCA2 mutation","volume":"99","author":"Narod","year":"2008","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.02.001_bib40","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1940-6207.CAPR-10-0397","article-title":"Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families","volume":"4","author":"Thorne","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"12","key":"10.1053\/j.seminoncol.2017.02.001_bib41","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jnci\/djm005","article-title":"Prostate cancer progression and survival in BRCA2 mutation carriers","volume":"99","author":"Tryggvadottir","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1053\/j.seminoncol.2017.02.001_bib42","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0022-5347(17)41192-X","article-title":"Assessment of screening for prostate cancer using the digital rectal examination","volume":"141","author":"Chodak","year":"1989","journal-title":"J Urol"},{"issue":"10","key":"10.1053\/j.seminoncol.2017.02.001_bib43","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jama.1994.03520100035030","article-title":"Screening for prostate cancer. A decision analytic view","volume":"272","author":"Krahn","year":"1994","journal-title":"JAMA"},{"issue":"17","key":"10.1053\/j.seminoncol.2017.02.001_bib44","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.02.001_bib45","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2005.04.015","article-title":"Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2\u201310 ng\/ml: systematic review and meta-analysis","volume":"48","author":"Roddam","year":"2005","journal-title":"Eur Urol"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.02.001_bib46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.294.1.66","article-title":"Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng\/ml or lower","volume":"294","author":"Thompson","year":"2005","journal-title":"JAMA"},{"issue":"16","key":"10.1053\/j.seminoncol.2017.02.001_bib47","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.1992.03480160073037","article-title":"Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease","volume":"267","author":"Carter","year":"1992","journal-title":"JAMA"},{"issue":"13","key":"10.1053\/j.seminoncol.2017.02.001_bib48","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminoncol.2017.02.001_bib49","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1053\/j.seminoncol.2017.02.001_bib50","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jnci\/djr028","article-title":"An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection","volume":"103","author":"Vickers","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib51","unstructured":"Lin K, Croswell JM, Koenig H, et al. Prostate-Specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. (Evidence Syntheses, No. 90.) Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK82303\/"},{"issue":"13","key":"10.1053\/j.seminoncol.2017.02.001_bib52","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"issue":"9959","key":"10.1053\/j.seminoncol.2017.02.001_bib53","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.02.001_bib54","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.eururo.2011.08.002","article-title":"Towards an optimal interval for prostate cancer screening","volume":"61","author":"van Leeuwen","year":"2012","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib55","doi-asserted-by":"crossref","first-page":"c4543","DOI":"10.1136\/bmj.c4543","article-title":"Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials","volume":"341","author":"Djulbegovic","year":"2010","journal-title":"BMJ"},{"issue":"6","key":"10.1053\/j.seminoncol.2017.02.001_bib56","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1464-410X.2010.10032.x","article-title":"Screening for prostate cancer: an updated Cochrane systematic review","volume":"107","author":"Ilic","year":"2011","journal-title":"BJU Int"},{"issue":"5","key":"10.1053\/j.seminoncol.2017.02.001_bib57","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.juro.2010.12.032","article-title":"A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng\/ml prostate specific antigen range","volume":"185","author":"Catalona","year":"2011","journal-title":"J Urol"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.02.001_bib58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.juro.2015.01.091","article-title":"Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men","volume":"194","author":"de la Calle","year":"2015","journal-title":"J Urol"},{"issue":"36","key":"10.1053\/j.seminoncol.2017.02.001_bib59","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","article-title":"Can urinary PCA3 supplement PSA in the early detection of prostate cancer?","volume":"32","author":"Wei","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.02.001_bib60","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.pcan.4500232","article-title":"Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer","volume":"1","author":"Partin","year":"1998","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.02.001_bib61","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.urology.2005.10.052","article-title":"A meta-analysis of the performance characteristics of the free prostate-specific antigen test","volume":"67","author":"Lee","year":"2006","journal-title":"Urology"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib62","first-page":"13","article-title":"What is multiparametric-MRI of the prostate and why do we need it?","volume":"7","author":"Barrett","year":"2015","journal-title":"J Imag Intervent Rad"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib63","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2214\/AJR.13.11046","article-title":"Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis","volume":"202","author":"de Rooij","year":"2014","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1053\/j.seminoncol.2017.02.001_bib64","doi-asserted-by":"crossref","first-page":"509","DOI":"10.6004\/jnccn.2016.0060","article-title":"NCCN guidelines insights: prostate cancer early detection, version 2.2016","volume":"14","author":"Carroll","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib65","doi-asserted-by":"crossref","first-page":"d7894","DOI":"10.1136\/bmj.d7894","article-title":"Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study","volume":"344","author":"Rosario","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.02.001_bib66","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7326\/0003-4819-149-3-200808050-00009","article-title":"Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force","volume":"149","author":"Lin","year":"2008","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1053\/j.seminoncol.2017.02.001_bib67","doi-asserted-by":"crossref","first-page":"762","DOI":"10.7326\/0003-4819-155-11-201112060-00375","article-title":"Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force","volume":"155","author":"Chou","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib68","series-title":"U.S. Preventive Services Task Force evidence syntheses, formerly systematic evidence reviews. Treatments for localized prostate cancer: systematic review to update the 2002 U.S. Preventive Services Task Force recommendation","author":"Chou","year":"2011"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1053\/j.seminoncol.2017.02.001_bib70","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1001\/jama.2011.1891","article-title":"Prostate cancer screening\u2014the evidence, the recommendations, and the clinical implications","volume":"306","author":"Chou","year":"2011","journal-title":"JAMA"},{"issue":"6","key":"10.1053\/j.seminoncol.2017.02.001_bib71","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.juro.2015.06.075","article-title":"Effect of the USPSTF grade d recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States","volume":"194","author":"Barocas","year":"2015","journal-title":"J Urol"},{"issue":"22","key":"10.1053\/j.seminoncol.2017.02.001_bib72","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2015.61.6532","article-title":"National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening","volume":"33","author":"Drazer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.02.001_bib73","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaoncol.2015.6310","article-title":"Recent trends in PSA testing and prostate cancer incidence: a look at context","volume":"2","author":"Etzioni","year":"2016","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1053\/j.seminoncol.2017.02.001_bib74","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1001\/jama.2015.14905","article-title":"Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations","volume":"314","author":"Jemal","year":"2015","journal-title":"JAMA"},{"issue":"19","key":"10.1053\/j.seminoncol.2017.02.001_bib75","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.2015.7273","article-title":"Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations","volume":"314","author":"Sammon","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.02.001_bib76","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamainternmed.2015.7901","article-title":"Differences in prostate-specific antigen testing among urologists and primary care physicians following the 2012 USPSTF recommendations","volume":"176","author":"Zavaski","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1053\/j.seminoncol.2017.02.001_bib77","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the G\u00f6teborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1053\/j.seminoncol.2017.02.001_bib78","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial","volume":"279","author":"Catalona","year":"1998","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.seminoncol.2017.02.001_bib79","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schroder","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.seminoncol.2017.02.001_bib80","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1002\/cncr.26104","article-title":"Comorbidity and competing risks for mortality in men with prostate cancer","volume":"117","author":"Daskivich","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1053\/j.seminoncol.2017.02.001_bib81","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/cncr.25751","article-title":"Overtreatment of men with low-risk prostate cancer and significant comorbidity","volume":"117","author":"Daskivich","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.02.001_bib82","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2008.03.104","article-title":"The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam","volume":"54","author":"Gosselaar","year":"2008","journal-title":"Eur Urol"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib83","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3322\/caac.20066","article-title":"American Cancer Society guideline for the early detection of prostate cancer: update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1053\/j.seminoncol.2017.02.001_bib84","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","article-title":"Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low-vs high-grade prostate cancer","volume":"83","author":"Ankerst","year":"2014","journal-title":"Urology"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.02.001_bib85","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","article-title":"Early detection of prostate cancer: AUA Guideline","volume":"190","author":"Carter","year":"2013","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2017.02.001_bib86","doi-asserted-by":"crossref","first-page":"691380","DOI":"10.1155\/2012\/691380","article-title":"Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007","volume":"2012","author":"Li","year":"2012","journal-title":"Prostate Cancer"},{"issue":"17","key":"10.1053\/j.seminoncol.2017.02.001_bib87","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1001\/archinternmed.2009.282","article-title":"A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices","volume":"169","author":"Howard","year":"2009","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.02.001_bib88","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/0003-4819-158-3-201302050-00003","article-title":"Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms","volume":"158","author":"Gulati","year":"2013","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1053\/j.seminoncol.2017.02.001_bib89","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/jama.284.11.1399","article-title":"Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection","volume":"284","author":"Ross","year":"2000","journal-title":"JAMA"},{"issue":"18","key":"10.1053\/j.seminoncol.2017.02.001_bib90","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa1011967","article-title":"Radical prostatectomy versus watchful waiting in early prostate cancer","volume":"364","author":"Bill-Axelson","year":"2011","journal-title":"N Engl J Med"},{"issue":"45","key":"10.1053\/j.seminoncol.2017.02.001_bib91","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/jncimonographs\/lgs041","volume":"2012","author":"Wilt","year":"2012","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.02.001_bib92","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.juro.2008.11.117","article-title":"Prostate specific antigen testing among the elderly\u2014when to stop?","volume":"181","author":"Schaeffer","year":"2009","journal-title":"J Urol"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.02.001_bib93","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.juro.2014.03.032","article-title":"Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening","volume":"192","author":"Vertosick","year":"2014","journal-title":"J Urol"},{"issue":"15","key":"10.1053\/j.seminoncol.2017.02.001_bib94","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/jnci\/dji205","article-title":"Prostate-specific antigen levels in the United States: implications of various definitions for abnormal","volume":"97","author":"Welch","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1053\/j.seminoncol.2017.02.001_bib95","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/0003-4819-156-8-201204170-00010","article-title":"National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer","volume":"156","author":"Ganz","year":"2012","journal-title":"Ann Intern Med"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416300884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416300884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T11:49:44Z","timestamp":1568807384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775416300884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0093775416300884"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2017.02.001","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2017.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}